Cargando…

Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs

Using the crystal structure of SARS-CoV-2 papain-like protease (PL(pro)) as a template, we developed a pharmacophore model of functional centers of the PL(pro) inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kouznetsova, Valentina L., Zhang, Aidan, Tatineni, Mahidhar, Miller, Mark A., Tsigelny, Igor F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2020
Materias:	Bioinformatics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505060/ https://www.ncbi.nlm.nih.gov/pubmed/32999768 http://dx.doi.org/10.7717/peerj.9965

Ejemplares similares

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022)

MERS‐CoV papain-like protease (PL(pro)): expression, purification, and spectroscopic/thermodynamic characterization
por: Malik, Ajamaluddin, et al.
Publicado: (2017)

Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (M(pro)) and Papain-like Protease (PL(pro))
por: Omage, Folorunsho Bright, et al.
Publicado: (2023)

Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease
por: Xu, Yunxia, et al.
Publicado: (2021)

Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning
por: Gantla, Maanaskumar R., et al.
Publicado: (2023)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Metallodrug Profiling against SARS‐CoV‐2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain‐like Protease PL(pro)
por: Gil‐Moles, Maria, et al.
Publicado: (2021)

FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy
por: Zali, Hakimeh, et al.
Publicado: (2019)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M(pro)) by using STD-NMR spectroscopy, in silico studies and antiviral assays
por: Khan, Abdul Mateen, et al.
Publicado: (2023)

The Autocatalytic Release of a Putative RNA Virus Transcription Factor from Its Polyprotein Precursor Involves Two Paralogous Papain-like Proteases That Cleave the Same Peptide Bond
por: Ziebuhr, John, et al.
Publicado: (2001)

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M(pro)
por: Balaramnavar, Vishal M., et al.
Publicado: (2020)

Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery
por: Ray, Abhik Kumar, et al.
Publicado: (2022)

Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme
por: Bahadur Gurung, Arun, et al.
Publicado: (2020)

Role of Papain-Like Cysteine Proteases in Plant Development
por: Liu, Huijuan, et al.
Publicado: (2018)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

Repurposing the McoTI-II Rigid Molecular Scaffold in to Inhibitor of ‘Papain Superfamily’ Cysteine Proteases
por: Mishra, Manasi, et al.
Publicado: (2020)

Correction: Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M(pro)
por: Balaramnavar, Vishal M., et al.
Publicado: (2020)

COVID-19 Multi-Targeted Drug Repurposing Using Few-Shot Learning
por: Liu, Yang, et al.
Publicado: (2021)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
por: O’Reilly, Paul G., et al.
Publicado: (2016)

Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
por: Lo, Yu-Chen, et al.
Publicado: (2017)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
por: Zulfiqar, Zikra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_slpev5h2iso0uutaam30v2lvbv